- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05130138
Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia (PHARM-LMC)
Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia: PHARM-LMC Study
The aim of this trial is therefore to identify concomitant treatments with taking Tyrosine Kinase Inhibitor (=TKI) in the indication of Chronic Myeloid Leukemia (CML), whatever the stage of the disease, via pharmaceutical conciliation. These concomitant treatments as well as their dosages will be correlated with the TKI dosage since patients must have a sufficient residual concentration to be considered effective and to confirm adherence to treatment, the leading cause of treatment failure.
In the event of unsatisfactory results, pharmaceutical interventions may take place: changes in treatments (TKI and not TKI) and / or dosages. In case of modification, a new dosage of TKI should be carried out.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Chronic myeloid leukemia (CML) is a clonal myeloproliferative syndrome with an estimated incidence of 0.8-1 cases per 100,000 person-years in 2018 in France. CML is characterized by the transformation of a pluripotent stem cell resulting in an increase in myeloid and erythroid lineages and megakaryocytes in peripheral blood as well as myeloid hyperplasia in the bone marrow.
In the absence of treatment, the disease, which begins in a chronic phase over a few years, progresses to an acceleration phase, before reaching an acute phase, known as a blast crisis, with a poor prognosis. This abnormal proliferation of white blood cells results from the reciprocal translocation (exchange) between chromosomes 9 and 22. This exchange brings two normally distinct genes into contact: the (breakpoint cluster region) BCR gene and the abl gene (Tyrosine-protein kinase), which will form an abnormal gene called "fusion Bcr-abl". This gene encodes a fusion protein with deregulated tyrosine kinase activity that activates various mechanisms involved in cell multiplication.
Since the 1990s, the arrival of the first tyrosine kinase inhibitor (TKI), imatinib, has radically changed patient management. Indeed, according to Public Health France, this treatment has allowed the majority of patients to remain in the chronic phase for a long time. Patient survival has therefore increased dramatically as the life expectancy of patients with CML taking their treatment regularly approaches that of the general population.
However, even though several generations of TKI have been developed, certain toxicities may lead to discontinuation of treatment, or to a modification of the dose. Indeed, a meta-analysis published in June 2020 shows that second and third generation of TKI improve the major molecular response by 3 months, but are associated with a recrudescence of thrombocytopenia, cardiovascular, pancreatic and hepatic events. First generation imatinib therefore remains the best option for patients with co-morbidities despite the frequent presence of headaches, digestive disorders, and cramps.
It has therefore always been customary to change the TKI or modify the prescribed doses, while the side effects or ineffectiveness of these inhibitors could be explained by drug interactions, or be related to the use of herbal medicine. Indeed, TKIs are metabolized by the cytochrome P450 system. The activity of this cytochrome is not only different from one person to another, but can also be affected by other treatments. For example, some treatments will inhibit the activity of this cytochrome P450, increasing the exposure of TKIs in plasma. The pharmacokinetics of the drug will therefore depend on these concomitant treatments and their influence, among others, on cytochrome P450.
In addition, the median age at diagnosis is respectively 61 years for men and 62 years for women. These patients are therefore often carriers of other chronic diseases and are have multiple treatments.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sandrine Menguy, MD, PhD
- Phone Number: +33 0477917136
- Email: sandrine.menguy@chu-st-etienne.fr
Study Contact Backup
- Name: Mathilde Maison, MsC
- Phone Number: +33 0477917136
- Email: mathilde.maison@chu-st-etienne.fr
Study Locations
-
-
-
Saint-Étienne, France, 42055
- Recruiting
- CHU DE SAINT-ETIENNE
-
Contact:
- Sandrine Menguy, MD, PhD
- Phone Number: +33 0477917136
- Email: sandrine.menguy@chu-st-etienne.fr
-
Contact:
- Mathilde Maison, MsC
- Phone Number: +33 0477917136
- Email: mathilde.maison@chu-st-etienne.fr
-
Sub-Investigator:
- Karine AUGEUL MEUNIER
-
Sub-Investigator:
- Silvia Maria BEZSERA
-
Sub-Investigator:
- Emilie CHALAYER
-
Sub-Investigator:
- Philippe COLLET
-
Sub-Investigator:
- Jérôme CORNILLON
-
Sub-Investigator:
- Caroline LEJEUNE
-
Sub-Investigator:
- Thierry MURON
-
Sub-Investigator:
- Gilbert SOGLU
-
Sub-Investigator:
- Emmanuelle TAVERNIER TARDY
-
Sub-Investigator:
- Pauline DOUCEY
-
Sub-Investigator:
- Fabien FORGES
-
Sub-Investigator:
- Sophie KALFON
-
Sub-Investigator:
- Agnès MACE
-
Sub-Investigator:
- Denis Guyotat
-
Sub-Investigator:
- Ludovic Fouillet
-
Sub-Investigator:
- Fressia Honeyman
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Major patient;
- Patient affiliated to a social security scheme;
- Patient suffering from Chronic Myeloid Leukemia, taking a Tyrosine Kinase Inhibitor (Imatinib, Nilotinib, Dasatinib, or Bosutinib);
- Molecular response < 4,5 Log;
Exclusion Criteria:
- Legal incapacity or limited capacity ; Medical or psychological incapacity or limited capacity;
- Not able to read and/or to write French;
- Patient taking Ponatinib.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pharmaceutical conciliation
Patients with Chronic Myeloid Leukemia taking TKI with a molecular response < 4,5 Log will participate to pharmaceutical conciliation.
|
Patients with pharmacokinetic and/or pharmacodynamics interactions will be proposed to participate to educational sessions to discuss about treatments taken and modifications possibilities.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients for whom pharmaceutical interventions have been done
Time Frame: 12 months
|
Number of patients for whom pharmaceutical interventions have been done secondly to pharmaceutical conciliation will be reported.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Molecular response
Time Frame: 12 months
|
Molecular response will be reported via BCR-ABL transcript rate measured by quantitative polymerase chain reaction (qPCR) or digital polymerase chain reaction (PCR).
|
12 months
|
Concomitant treatments
Time Frame: 12 months
|
Concomitant treatments will be reported during 12 months.
|
12 months
|
Tyrosine kinase inhibitor observance
Time Frame: 12 months
|
Observance to Tyrosine kinase inhibitor will be measured with Girerd Questionnaire.
|
12 months
|
Side effects
Time Frame: 12 months
|
Number and description of sides effects will be reported.
|
12 months
|
Patients' satisfaction
Time Frame: 12 months
|
Patients' satisfaction will be measured with a visual scale from 0 to 10.
|
12 months
|
Patients' quality of life
Time Frame: 12 months
|
Patients' quality of life will be measured with the Quality of Life questionnaires (QLQ-C30) questionnaire.
The maximum score is 126, the minimum score is 30.
More the score is, worst the health state is.
|
12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Sandrine Menguy, MD, PhD, CHU DE SAINT-ETIENNE
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-0401
- 2021-A00942-39 (Other Identifier: Agence Nationale de Sécurité du Médicament et des produits de santé)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Myeloid Leukemia
-
Newcastle UniversityBristol-Myers Squibb; Institute of Cancer Research, United Kingdom; Newcastle-upon-Tyne... and other collaboratorsCompletedMyeloid Leukemia, Chronic, Chronic PhaseUnited Kingdom
-
Asan Medical CenterTerminatedLeukemia, Chronic Myeloid | Myeloid Leukemia, Chronic, Chronic Phase | Myeloid Leukemia, Chronic, Accelerated PhaseKorea, Republic of
-
Bristol-Myers SquibbTerminatedLeukemia, Myeloid, ChronicSweden, United Kingdom, Russian Federation, France, Germany, Belgium, Portugal, Finland, Norway, Spain, Italy
-
University of BolognaCompletedMyeloid Leukemia, Chronic, Chronic-PhaseItaly
-
Bristol-Myers SquibbWithdrawnMyeloid Leukemia, Chronic, Chronic-PhaseUnited States
-
PETHEMA FoundationCompleted
-
H. Lee Moffitt Cancer Center and Research InstituteIncyte Corporation; H. Jean Khoury Cure CML ConsortiumRecruitingChronic Myeloid Leukemia, Chronic Phase | Chronic Phase Chronic Myeloid LeukemiaUnited States
-
Emory UniversityTerminatedLeukemia | Chronic Myeloid Leukemia | Chronic Myelogenous LeukemiaUnited States
-
Fundacion Espanola para la Curacion de la Leucemia...Pfizer; Roche Farma, S.ATerminatedChronic Phase-Chronic Myeloid LeukemiaSpain
-
TakedaActive, not recruitingMyeloid Leukemia, Chronic, Chronic PhaseUnited States, Spain, Taiwan, Australia, Canada, Russian Federation, Sweden, Switzerland, Germany, United Kingdom, Poland, Korea, Republic of, Argentina, Hong Kong, Singapore, Italy, Chile, Czechia, Denmark, France, Portugal
Clinical Trials on Pharmaceutical intervention
-
Hospital de Clinicas de Porto AlegreRecruiting
-
Federal University of BahiaCompleted
-
University Hospital, GhentGlaxoSmithKline; University GhentCompletedChronic Obstructive Pulmonary Disease (COPD)Belgium
-
Federal University of BahiaCompletedPharmaceutical Care | Systemic Arterial Hypertension | PharmacotherapyBrazil
-
Universitaire Ziekenhuizen KU LeuvenCompletedHeart FailureBelgium
-
University Hospital, MontpellierCompletedOrthopaedic Surgery | TraumatologyFrance
-
Florida State UniversityBoston University; Children's Hospital of Philadelphia; University of Miami; Boston... and other collaboratorsCompletedAutism Spectrum DisorderUnited States
-
Hospital do Rim e HipertensãoCompletedRenal Transplant Graft Failure
-
Vastra Gotaland RegionNot yet recruitingGestational Diabetes
-
Albert Einstein Healthcare NetworkMerck Sharp & Dohme LLCRecruiting